Correlation of Endothelial Function and Early Coronary Artery Disease in Humans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00271492|
Recruitment Status : Completed
First Posted : January 2, 2006
Last Update Posted : April 30, 2010
|Condition or disease||Intervention/treatment||Phase|
|Endothelial Dysfunction||Drug: Atrasentan Drug: atrasentan||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||200 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Endothelin in the Coronary Circulation in Early Atherosclerosis in Humans|
|Study Start Date :||July 2001|
|Actual Primary Completion Date :||June 2006|
|Actual Study Completion Date :||January 2008|
Active Comparator: I
Qualifying patients took Atrasentan, 1 pill per day for 6 months, to determine if it had a favorable affect on patients who took it over those who were randomized to placebo.
1 10mg capsule to be taken daily for 6 month study period.
Other Name: XinlayDrug: Atrasentan
1 10mg capsule per day for the 6 month study period.
Other Name: Xinlay
Placebo Comparator: 2
placebo group to be compared to the actual medication
One 10 mg capsule per day for 6 month study period
Other Name: Xinlay
- To find out what effects (good and bad) the medication Atrasentan has on the heart [ Time Frame: 6 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00271492
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Amir Lerman, M.D.||Mayo Clinic|